Literature DB >> 26590832

Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review.

Shadi Al-Khalil1, David Boothe1, Trey Durdin1, Sowmya Sunkara1, Phillip Watkins1, Shengping Yang1, Allan Haynes1, Werner de Riese2.   

Abstract

PURPOSE: To study the interaction between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
METHODS: In this study, we performed a chart review of a cohort of 448 biopsy naive men. These men received a multi-core biopsy at our institution due to increased prostate-specific antigen (PSA) serum levels (>4 ng/ml) and/or suspicious findings on digital rectal examination in the years between 2008 and 2013. Utilizing PSA and transrectal ultrasound (TRUS) prostate volume, we obtained the PSA density (PSAD) for each individual. PSAD was calculated by dividing serum PSA concentration by TRUS prostate volume.
RESULTS: Large prostates >65 g may secrete enough PSA to have a PSAD above the suggested cutoff of 0.15, yet 50 % patients have no histologic evidence of PCa, whereas prostates <35 g and an elevated PSAD of above 0.15 will have histologic evidence of PCa 70 % of the time.
CONCLUSIONS: These results suggest that BPH in large prostates may be protective of PCa. The interaction of the different prostate zones, in particular the transition zone and peripheral zone, may play a significant role in the phenomenon observed in this study. However, sampling error may introduce bias that 12-16 core biopsies in larger prostates may be more likely missing the cancer lesion.

Entities:  

Keywords:  Benign prostate hyperplasia (BPH); PSA density; Prostate cancer; Prostate-specific antigen

Mesh:

Substances:

Year:  2015        PMID: 26590832     DOI: 10.1007/s11255-015-1146-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

Authors:  Maria Frånlund; Sigrid Carlsson; Johan Stranne; Gunnar Aus; Jonas Hugosson
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

Review 2.  Prospective evaluation of prostate specific antigen density and systematic biopsy for detecting prostate cancer in Japanese patients with normal rectal examinations and intermediate prostate specific antigen levels.

Authors:  Y Arai; H Maeda; S Ishitoya; K Okubo; T Okada; Y Aoki
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

Review 3.  BPH: epidemiology and comorbidities.

Authors:  Kevin T McVary
Journal:  Am J Manag Care       Date:  2006-04       Impact factor: 2.229

4.  The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma.

Authors:  A G Ayala; J Y Ro; R Babaian; P Troncoso; D J Grignon
Journal:  Am J Surg Pathol       Date:  1989-01       Impact factor: 6.394

5.  The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.

Authors:  Leonard S Marks; Claus G Roehrborn; Eric Wolford; Timothy H Wilson
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

6.  Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.

Authors:  Stephen J Freedland; William B Isaacs; Elizabeth A Platz; Martha K Terris; William J Aronson; Christopher L Amling; Joseph C Presti; Christopher J Kane
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 7.  The association of benign prostatic hyperplasia and cancer of the prostate.

Authors:  D G Bostwick; W H Cooner; L Denis; G W Jones; P T Scardino; G P Murphy
Journal:  Cancer       Date:  1992-07-01       Impact factor: 6.860

8.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

Authors:  M C Benson; I S Whang; A Pantuck; K Ring; S A Kaplan; C A Olsson; W H Cooner
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

9.  Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy?

Authors:  Jong Jin Oh; Seong Jin Jeong; Chang Wook Jeong; Seok-Soo Byun; Sung Kyu Hong; Gheeyoung Choe; Sang Eun Lee
Journal:  Prostate       Date:  2012-05-14       Impact factor: 4.104

10.  Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?

Authors:  M Ohori; J K Dunn; P T Scardino
Journal:  Urology       Date:  1995-11       Impact factor: 2.649

View more
  10 in total

1.  Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view.

Authors:  Shadi Khalil; Werner de Riese
Journal:  World J Urol       Date:  2017-03-17       Impact factor: 4.226

2.  The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3.

Authors:  Hai Zhu; Xue-Fei Ding; Sheng-Ming Lu; Ning Ding; Shi-Yi Pi; Zhen Liu; Qin Xiao; Liang-Yong Zhu; Yang Luan; Yue-Xing Han; Hao-Peng Chen; Zhong Liu
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Association Between Prostate Size and MRI Determined Quantitative Prostate Zonal Measurements.

Authors:  Jake Sellers; Rachel Wagstaff; Naseem Helo; Werner T W de Riese
Journal:  Res Rep Urol       Date:  2022-06-30

4.  Association of prostate volume with incidence and aggressiveness of prostate cancer.

Authors:  Shadi Al-Khalil; Christine Ibilibor; James Thomas Cammack; Werner de Riese
Journal:  Res Rep Urol       Date:  2016-10-26

5.  Histological changes of the peripheral zone in small and large prostates and possible clinical implications.

Authors:  Jonathan A Guzman; Pranav Sharma; Lisa A Smith; John D Buie; Werner T de Riese
Journal:  Res Rep Urol       Date:  2019-03-21

6.  Prostate resected weight and postoperative prostate cancer incidence after transurethral resection of the prostate: A population-based study.

Authors:  Fu-Chao Liu; Kuo-Chun Hua; Jr-Rung Lin; See-Tong Pang; Huang-Ping Yu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

7.  Quantitative measurements of prostatic zones by MRI and their dependence on prostate size: possible clinical implications in prostate cancer.

Authors:  Jake Sellers; Rachel G Wagstaff; Naseem Helo; Werner T W de Riese
Journal:  Ther Adv Urol       Date:  2021-03-31

Review 8.  Any Correlation Between Prostate Volume and Incidence of Prostate Cancer: A Review of Reported Data for the Last Thirty Years.

Authors:  Justine R Yamashiro; Werner T W de Riese
Journal:  Res Rep Urol       Date:  2021-10-10

9.  Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.

Authors:  Jitian Li; Liping Dai; Ningjing Lei; Mengtao Xing; Pei Li; Chenglin Luo; Carlos A Casiano; Jian-Ying Zhang
Journal:  Oncotarget       Date:  2016-07-12

10.  Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone.

Authors:  Junxiao Liu; Biao Dong; Wugong Qu; Jiange Wang; Yue Xu; Shuanbao Yu; Xuepei Zhang
Journal:  Sci Rep       Date:  2020-03-20       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.